New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
08:33 EDTACT, FRXActavis, Forest announce merger consideration election results
Actavis (ACT) and Forest Laboratories (FRX) announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration they will receive in connection with Actavisí pending acquisition of Forest. Subject to regulatory approval and other customary closing conditions, the closing of the acquisition is expected to be effective on July 1. Based on available information as of the Election Deadline, the preliminary merger consideration election results are as follows: holders of approximately 13.81% of the outstanding shares of Forest common stock elected the Standard Election Consideration; holders of approximately 0.44% of the outstanding shares of Forest common stock elected the Cash Election Consideration; holders of approximately 72.78% of the outstanding shares of Forest common stock elected the Stock Election Consideration; holders of approximately 12.97% of the outstanding shares of Forest common stock failed to make a valid election prior to the Election Deadline, and therefore are deemed to have elected the Standard Election Consideration.
News For ACT;FRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:04 EDTACTShire granted petitiion by U.S. Supreme Court
Subscribe for More Information
January 26, 2015
17:34 EDTACTActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
07:34 EDTACTActavis to acquire Auden Mckenzie for GBP306M accretive in FY15
Subscribe for More Information
January 22, 2015
05:57 EDTACTActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTACTGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTACTActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
05:34 EDTACTActavis reports positive Phase III results for cariprazine
Gedeon Richter and Actavis announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. There were 101 patients randomized to cariprazine 3 to 9 mg per day and 99 randomized to placebo. The primary efficacy measure was time to first relapse during the double-blind period. There were 25 relapses in the cariprazine group versus 47 relapses in the placebo group. Treatment with cariprazine was associated with a 55% reduction in risk of relapse versus placebo.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use